BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 257.12% | 217.43% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.69% | 80.33% | -- | -- | -- |
| Operating Income | -90.69% | -80.33% | -- | -- | -- |
| Income Before Tax | -90.50% | -80.47% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.50% | -80.47% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.50% | -80.47% | -- | -- | -- |
| EBIT | -90.69% | -80.33% | -- | -- | -- |
| EBITDA | -90.81% | -80.45% | -- | -- | -- |
| EPS Basic | 98.17% | 96.38% | -- | -- | -- |
| Normalized Basic EPS | 98.17% | 96.38% | -- | -- | -- |
| EPS Diluted | 98.17% | 96.38% | -- | -- | -- |
| Normalized Diluted EPS | 98.17% | 96.38% | -- | -- | -- |
| Average Basic Shares Outstanding | 36,290.00% | 44,537.66% | -- | -- | -- |
| Average Diluted Shares Outstanding | 36,290.00% | 44,537.66% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |